Anti-CD25 Monoclonal Antibody
Phase 3
Anti-CD25 Monoclonal Antibody is one of 42 therapeutic programs targeting Graft Versus Host Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
48 competitors in Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Neoral
NovartisApproved
Medrol
PfizerApproved
Selzentry
GSKApproved
Gleevec
NovartisApproved
Olumiant
Eli LillyApproved
Defitelio
Jazz PharmaceuticalsApproved
Nipent
PfizerApproved
Qvar
SSchering-Plough
Approved
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Graft Versus Host Disease1 trial
A Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial of Anti-CD25 Monoclonal Antibody Versus Methotrexate for the Prevention of Acute Graft-Versus-Host Disease After Haploidentical Hematopoietic Stem Cell Transplantation
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 3·NCT07689630·186 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]